Star Health and Allied Insurance posted a net profit of INR 2.6 billion in the second quarter of fiscal year 2027, marking a 233% increase. The growth was driven by higher investment income and improved operational efficiency. Analysts have maintained a positive outlook, but investors should weigh this against intense competition in the Indian health insurance sector.
Star Health and Allied Insurance delivered a strong financial performance in the second quarter of the 2027 fiscal year. The insurer reported a Profit After Tax of INR 2.6 billion, a sharp increase from the previous year. This performance was supported by a 15% growth in insurance revenue, which reached INR 50.7 billion, alongside a 19% expansion in gross premiums.
A key driver of this success was the improvement in the company's core operations. The insurance service result climbed 95% to INR 3.8 billion. Furthermore, the company managed its costs effectively, with the combined ratio—a metric measuring the percentage of premiums spent on claims and expenses—improving by 290 basis points to 98%. This improvement suggests that the company is currently better at managing its underwriting and administrative costs than it was in previous periods.
Beyond its core insurance business, investment income acted as a significant tailwind. The company reported INR 2.7 billion in investment income, a 62% jump compared to the same quarter last year. This unexpected boost in non-operating income played a major role in the overall profit increase for the quarter.
Despite the positive quarterly figures, the health insurance sector in India remains a challenging landscape. The industry is characterized by intense competition between private insurers, established public sector companies, and new market entrants, which often exerts pressure on pricing and market share. Additionally, the regulatory environment is evolving; bodies like the Insurance Regulatory and Development Authority of India (IRDAI) are consistently tightening guidelines around claim settlement transparency, product design, and customer grievances. Any changes in these regulations or a rise in claim ratios could impact the profit margins of health insurers.
In a recent report, Motilal Oswal reiterated a positive view on the stock, projecting a 46% compound annual growth rate in profit between fiscal years 2026 and 2028, with a target price of INR 690. Investors tracking this stock should focus on several monitorables in the coming quarters. These include the company’s ability to sustain its improved combined ratio, its claim settlement speed, how it manages competition from rivals, and any potential shifts in regulatory policies that could affect the industry's cost structure.